- Exchange: Frankfurt
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Ligand Pharmaceuticals Inc
+ Add to WatchlistLGDN:GR
21.537 EUR 0.622 2.97%As of 11:39:24 ET on 05/24/2013.
Snapshot for Ligand Pharmaceuticals Inc (LGDN)
| Open: | 21.400 | Day's Range: | 21.345 - 22.000 | Volume: | 713 |
|---|---|---|---|---|---|
| Previous Close: | 20.915 | 52wk Range: | 9.565 - 22.000 | 1-Yr Rtn: | +140.40% |
Key Statistics for LGDN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | 49.6851 |
| Relative P/E vs. DAX | - |
| Earnings Per Share (USD) (ttm) | - |
| Est. EPS (USD) (12/2013) | 0.5600 |
| Est. PEG Ratio | 1.7133 |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 40 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend (USD) | 15.0000 |
| Last Dividend | 04/03/2007 |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for LGDN
Company Profile & Key Executives for LGDN
Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.
| John L HigginsPresident/CEO | Mathew W Foehr "Matt"Exec VP/COO |
| John P SharpVP:Finance/CFO | Charles S BerkmanVP/Secretary/General Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
LGDN News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page